Extreme Medicine

REVIEW

Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines

Bugaev-Makarovskiy NA, Ershov PV, Volkova AG, Makarova AS, Keskinov AA

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Pavel V. Ershov
Pogodinskaya, 10, d. 1, Moscow, 119121, Russia; ur.abmfpsc@vohsrep

About paper

Author contribution: all authors made equal contributions to the review preparation, writing, and editing

Received: 2023-05-10 Accepted: 2023-05-29 Published online: 2023-06-28

Table 1. The main results of the completed clinical trials of DC-vaccines

Table 2. Open-label clinical trials of the DC- and NA-vaccine efficacy (active, not recruiting)

Table 3. Open-label clinical trials of the DC-vaccine efficacy (recruiting)

Link to the next paper will be sent to the indicated e-mail's:

REVIEW Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines

Bugaev-Makarovskiy NA, Ershov PV, Volkova AG, Makarova AS, Keskinov AA

Published in "Bulletin of RSMU" 2, 2023

I want to receive a copy of this message

Vancouver style

Bugaev-Makarovskiy NA, Ershov PV, Volkova AG, Makarova AS, Keskinov AA. Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines. Extreme Medicine. 2023; (2): 5–14. DOI: 10.47183/mes.2023.019

Harvard style

Bugaev-Makarovskiy, N. A., Ershov, P. V., Volkova, A. G., Makarova, A. S. and Keskinov, A. A. (2023), "Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines", Extreme Medicine, no. 2, p. 5–14. DOI: 10.47183/mes.2023.019

Remember me

Forgot password?

I accept Editorial Policies of the journal

Archive

2023 / 02

REVIEW

Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines